Valuation: argenx SE

Capitalization 43.39B 51.48B 39.71B 37.73B 69.96B 4,672B 72.33B 458B 183B 2,246B 193B 189B 7,893B P/E ratio 2025 *
47.8x
P/E ratio 2026 * 28.9x
Enterprise value 40.48B 48.04B 37.05B 35.21B 65.28B 4,359B 67.49B 427B 171B 2,096B 180B 176B 7,364B EV / Sales 2025 *
11.3x
EV / Sales 2026 * 7.74x
Free-Float
99.23%
Yield 2025 *
0.02%
Yield 2026 * 0.04%
1 day-1.16%
1 week-2.34%
Current month-0.43%
1 month+4.32%
3 months-8.10%
6 months+26.68%
Current year-2.23%
1 week 683.8
Extreme 683.8
730.2
1 month 660.4
Extreme 660.4
737
Current year 660.4
Extreme 660.4
737
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 9.23
Extreme 9.23
810
Manager TitleAgeSince
Chief Executive Officer 54 15/07/2008
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Director/Board Member 54 01/07/2014
Chairman 68 15/10/2008
Director/Board Member 76 13/05/2015
Change 5d. change 1-year change 3-years change Capi.($)
-1.16%-2.34%+13.14%+100.74% 51.64B
+0.78%+7.97%+74.30%+13.78% 43.87B
-1.08%-3.79%+83.58%+639.61% 31.68B
+0.13%+0.64%-4.39%-23.45% 27.33B
+3.45%+11.95%+89.91%-35.86% 21.18B
-2.92%-6.25%+37.09%-30.90% 19.02B
+0.18%+9.06%+141.59% - 13.04B
-0.47%+4.26%+62.97%+136.40% 12.45B
-0.93%-0.11%+29.85%+140.84% 11.57B
+1.44%+6.93%-19.18%+644.93% 11.76B
Average -0.05%+1.87%+50.89%+176.23% 24.35B
Weighted average by Cap. -0.14%+1.11%+48.56%+151.82%

Financials

2025 *2026 *
Net sales 3.59B 4.26B 3.28B 3.12B 5.78B 386B 5.98B 37.86B 15.11B 186B 15.96B 15.63B 652B 5.03B 5.97B 4.61B 4.38B 8.11B 542B 8.39B 53.1B 21.2B 260B 22.39B 21.93B 915B
Net income 978M 1.16B 895M 850M 1.58B 105B 1.63B 10.32B 4.12B 50.63B 4.35B 4.26B 178B 1.76B 2.08B 1.61B 1.53B 2.83B 189B 2.93B 18.54B 7.4B 90.95B 7.82B 7.66B 320B
Net Debt -2.91B -3.45B -2.66B -2.53B -4.69B -313B -4.84B -30.68B -12.25B -150B -12.93B -12.67B -529B -4.45B -5.28B -4.08B -3.87B -7.18B -480B -7.42B -47.01B -18.77B -231B -19.82B -19.41B -810B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
Date Price Change Volume
11/02/26 700.80 -1.16% 50,149
10/02/26 709.00 +1.05% 55,291
09/02/26 701.60 +0.86% 56,798
06/02/26 695.60 -2.85% 88,325
05/02/26 716.00 -0.22% 81,780
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
709.00EUR
Average target price
815.58EUR
Spread / Average Target
+15.03%

Quarterly revenue - Rate of surprise